BBIO

MKT CAP:$17B

BridgeBio Pharma Inc

Market Cap

$17B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$82.66+$4.42 (+5.66%)

Jul 15, 2026

52W High $85.8952W Low $44.81

Company Details

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the trea...

Leadership

Neil Kumar Ph.D.Founder

Co-Founder, CEO & Director

Thomas Trimarchi Ph.D.

CFO & President

Charles J. Homcy M.D.Founder

Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director

Frank P. McCormick Ph.D.Founder

Co-Founder, Chairman of Oncology & Director

Maricel M. Apuli

Chief Accounting Officer

Uma Sinha Ph.D.

Chief Scientific Officer

Richard H. Scheller Ph.D.

Chairman of Research & Development

Eli M. Wallace Ph.D.

Chief Scientific Officer of Oncology

Eric Michael David J.D., M.D., Ph.D.

Chief Executive Officer of Gene Therapy

Matthew Outten CPC, MBA

Chief Commercial Officer

IPO Date

Jun 27, 2019

Website

bridgebio.com

Key Metrics TTM

Revenue

$222M

+5324.2% YoY

Net Income

-$536M

EPS (Diluted)

Free Cash Flow

-$454M

Revenue / Share

$1.17

Gross Margin

98.3%

Operating Margin

-267.2%

Net Margin

-241.4%

FCF Margin

-204.6%

P/S

75.8x

P/E

Revenue & Profitability

Valuation

Operating Cash Flow

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Revenue by Product

War Chest

Shares Outstanding

Revenue Per Employee

Revenue / Employee